Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Add as a preferred source on Google
GAITHERSBURG, Md., Feb. 20, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its fourth quarter and full year 2016 financial and operating results following the close of U.S. financial markets on Monday, February 27, 2017.
Conference call details are as follows:
| Date: | Monday, February 27, 2017 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 61206704 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” | |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, February 27, 2017, until midnight March 3, 2017 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 61206704 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until April 30, 2017 | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
